Axsome Therapeutics
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Axsome Therapeutics (AXSM) | 6.80B | -42.69 | 64.55 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 8.3% below Morningstar's fair value estimate.
Fair value
Axsome Therapeutics Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 1% premium over our quantitative fair value estimate of $140.06 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The company's valuation metrics undermine our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 1.5% sits in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.
The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -1.3%, for example, lies in the bottom 30% globally. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Axsome Therapeutics discussion 0 comments